FORM 4

1. Name and Address of Reporting Person\*

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Check this box if no longer subject to
Section 16. Form 4 or Form 5 obligations
may continue. See Instruction 1(b).

SIAIEMENT OF CHANGES IN B

SIAIEMENT OF CHANGES IN B

Filed pursuant to Section 16(a) of the Sec

OMB APPROVAL

OMB Number: 3235-0287

Estimated average burden hours per response: 0.5

5. Relationship of Reporting Person(s) to Issuer

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

2. Issuer Name and Ticker or Trading Symbol

MPM BioVentures 2014, L.P.				Iteos Therapeutics, Inc. [ ITOS ]						Check	Director X 10% Owner  Officer (give title Other (specify						
(Last) (First) (Middle) C/O MPM CAPITAL 450 KENDALL STREET				3. Date of Earliest Transaction (Month/Day/Year) 07/28/2020						below) below)							
(Street) CAMBRIDGE MA 02142				4. If Amendment, Date of Original Filed (Month/Day/Year)					6. Individ	Individual or Joint/Group Filing (Check Applicable Line)     Form filed by One Reporting Person     X Form filed by More than One Reporting Person							
(City)		(State)	(Zip)	- Noi	n-Deri	vati	ve Securities	Acqui	red.	Disposed (	of. or F	Benefic	ially Own	ed			
1. Title of Security (Instr. 3)			2. Transaction Date (Month/Day/Yea		n	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transa Code (I 8)	ction	4. Securities Acquired (A) or (D) (Instr. 3, 4 and 5)				5. Amount of Securities Beneficially Ow Following Repo Transaction(s)	Form:	Direct (D)   I rect (I)   I 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
								Code	v	Amount		(A) or (D)	Price	(Instr. 3 and 4)			instr. 4)
Common	Stock			07.	/28/20	20		С		1,269,230	1)(2)(3)(4)	Α	(2)(3)(4)	1,269,230	)		See Footnote <sup>(5)</sup>
Common	Stock			07.	/28/20	20		С		84,655(1)(	(2)(3)(4)	A	(2)(3)(4)	84,655			See Footnote <sup>(5)</sup>
Common	Stock			07.	/28/20	20		С		43,687(1)(	(2)(3)(4)	A	(2)(3)(4)	43,687			See Footnote <sup>(5)</sup>
Common	Stock			07.	/28/20	20		С		801,619(1)	)(2)(3)(4)	A	(2)(3)(4)	801,619			See Footnote <sup>(6)</sup>
Common	Stock			07.	/28/20	20		С		42,605(1)(	(2)(3)(4)	A	(2)(3)(4)	42,605			See Footnote <sup>(6)</sup>
Common	Stock			07.	/28/20	20		С		15,820(1)(	(2)(3)(4)	A	(2)(3)(4)	15,820			See Footnote <sup>(6)</sup>
Common	Stock			07.	/28/20	20		С		724,702(2)	(3)(4)(12)	A	(2)(3)(4)	1,993,932	2		See Footnote <sup>(5)</sup>
Common	Stock			07.	/28/20	20		С		48,336(2)(	3)(4)(12)	A	(2)(3)(4)	132,991			See Footnote <sup>(5)</sup>
Common	Stock			07.	/28/20	20		С		24,944(2)(	3)(4)(12)	A	(2)(3)(4)	68,381			See Footnote <sup>(5)</sup>
Common	Stock			07.	/28/20	20		С		457,706 <sup>(2)</sup>	(3)(4)(12)	A	(2)(3)(4)	1,259,325	5		See Footnote <sup>(6)</sup>
Common	Stock			07.	/28/20	20		С		24,326(2)(	3)(4)(12)	A	(2)(3)(4)	66,931			See Footnote <sup>(6)</sup>
Common	Stock			07.	/28/20	20		С		9,033(2)(3	)(4)(12)	A	(2)(3)(4)	24,853			See Footnote <sup>(6)</sup>
Common	Stock			07.	/28/20	20		P		89,955	5 <sup>(8)</sup>	A	\$19	2,083,887	7		See Footnote <sup>(8)</sup>
Common	Stock			07.	/28/20	20		P		5,994	(9)	A	\$19	138,985			See Footnote <sup>(9)</sup>
Common	Stock			07.	/28/20	20		P		3,096	10)	A	\$19	71,727			See Footnote <sup>(10)</sup>
Common	Stock			07.	/28/20	20		P		56,814	(11)	A	\$19	1,316,139	9		See Footnote <sup>(11)</sup>
Common	Stock			07.	/28/20	20		P		3,020	[12]	A	\$19	69,951			See Footnote <sup>(12)</sup>
Common Stock			07/28/2020		20		P	P 1,121 <sup>(13)</sup> A		\$19	25,974	25,974 I		See Footnote <sup>(13)</sup>			
			Table				e Securities A s, calls, warra							t			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Cod	nsaction le (Instr.	.   or	Number of Derivative (Anti- curities Acquired (Anti- Disposed of (D) str. 3, 4 and 5)	ve 6. Date	ration nth/Day	ercisable and Date y/Year)	Securiti	/ (Instr. 3	lying Derivativ		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(	Ownersh Form: Direct (D or Indire (I) (Instr.	Beneficial Ownership ct (Instr. 4)
Series B Preferred	(2)(3)(4)	07/28/2020		Cod	$\top$	(A)	(D) 3,824,591 <sup>(1)(2)(3)</sup>	Exe	rcisabl )(3)(4)	e Date (2)(3)(4)	Title	of Sha		(4) (2)(3)(4)	(Instr. 4)	I	See (5)
Stock	( )(=)(=)	57/20/2020					3,024,391(-)(-)(0)		, (- N T)	(-)(-)(-)	Stock	1,20		(=)(=)(=)		1	Footnote <sup>(5)</sup>

	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)														
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code ( 8)		Sec or D	umber of Derivative urities Acquired (A) isposed of (D) tr. 3, 4 and 5)	6. Date Exerc Expiration D (Month/Day/	ate	Securities	d Amount of Underlying Derivative Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)
	Security			Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		Reported Transaction(s) (Instr. 4)	(1) (111501. 4)	
Series B Preferred Stock	(2)(3)(4)	07/28/2020		С			255,094 <sup>(1)(2)(3)(4)</sup>	(2)(3)(4)	(2)(3)(4)	Common Stock	84,655(1)(2)(3)(4)	(2)(3)(4)	0	I	See Footnote <sup>(5)</sup>
Series B Preferred Stock	(2)(3)(4)	07/28/2020		С			131,645 <sup>(1)(2)(3)(4)</sup>	(2)(3)(4)	(2)(3)(4)	Common Stock	43,687(1)(2)(3)(4)	(2)(3)(4)	0	I	See Footnote <sup>(5)</sup>
Series B Preferred Stock	(2)(3)(4)	07/28/2020		С			2,415,530 <sup>(1)(2)(3)(4)</sup>	(2)(3)(4)	(2)(3)(4)	Common Stock	801,619(1)(2)(3)(4)	(2)(3)(4)	0	I	See Footnote <sup>(6)</sup>
Series B Preferred Stock	(2)(3)(4)	07/28/2020		С			128,384 <sup>(1)(2)(3)(4)</sup>	(2)(3)(4)	(2)(3)(4)	Common Stock	42,605(1)(2)(3)(4)	(2)(3)(4)	0	I	See Footnote <sup>(6)</sup>
Series B Preferred Stock	(2)(3)(4)	07/28/2020		С			47,674 <sup>(1)(2)(3)(4)</sup>	(2)(3)(4)	(2)(3)(4)	Common Stock	15,820(1)(2)(3)(4)	(2)(3)(4)	0	I	See Footnote <sup>(6)</sup>
Series B-2 Preferred Stock	(2)(3)(4)	07/28/2020		С			2,361,805 <sup>(2)(3)(4)(7)</sup>	(2)(3)(4)	(2)(3)(4)	Common Stock	724,702(2)(3)(4)(7)	(2)(3)(4)	0	I	See Footnote <sup>(5)</sup>
Series B-2 Preferred Stock	(2)(3)(4)	07/28/2020		С			157,529 <sup>(2)(3)(4)(7)</sup>	(2)(3)(4)	(2)(3)(4)	Common Stock	48,336(2)(3)(4)(7)	(2)(3)(4)	0	I	See Footnote <sup>(5)</sup>
Series B-2 Preferred Stock	(2)(3)(4)	07/28/2020		С			81,295 <sup>(2)(3)(4)(7)</sup>	(2)(3)(4)	(2)(3)(4)	Common Stock	24,944 <sup>(2)(3)(4)(7)</sup>	(2)(3)(4)	0	I	See Footnote <sup>(5)</sup>
Series B-2 Preferred Stock	(2)(3)(4)	07/28/2020		С			1,491,666 <sup>(2)(3)(4)(7)</sup>	(2)(3)(4)	(2)(3)(4)	Common Stock	457,706 <sup>(2)(3)(4)(7)</sup>	(2)(3)(4)	0	I	See Footnote <sup>(6)</sup>
Series B-2 Preferred Stock	(2)(3)(4)	07/28/2020		С			79,281 <sup>(2)(3)(4)(7)</sup>	(2)(3)(4)	(2)(3)(4)	Common Stock	24,326 <sup>(2)(3)(4)(7)</sup>	(2)(3)(4)	0	I	See Footnote <sup>(6)</sup>
Series B-2 Preferred Stock	(2)(3)(4)	07/28/2020		С			29,440 <sup>(2)(3)(4)(7)</sup>	(2)(3)(4)	(2)(3)(4)	Common Stock	9,033(2)(3)(4)(7)	(2)(3)(4)	0	I	See Footnote <sup>(6)</sup>

Stock						
		Reporting Person* res 2014, L.P.				
	M CAPITAI		(Middl	e)		
(Street)	RIDGE	MA	02147	2		
(City)		(State)	(Zip)			
	nd Address of	Reporting Person*				
(Last)	M CAPITA	(First)	(Middle	e)		
450 KEN	NDALL STI	REET				
(Street)	RIDGE	MA	0214	2		
(City)		(State)	(Zip)			
1. Name a		Reporting Person*				
(Last)	M CAPITA	(First)	(Middl	e)		
	NDALL STI					
(Street)	RIDGE	MA	02142	2		
(City)		(State)	(Zip)			
		Reporting Person* es 2014 (B),	L.P.			
(Last)	M CAPITA	(First)	(Middle	e)		
450 KEN	NDALL STI	REET				
(Street)	RIDGE	MA	02142	2		

(City)	(State)	(Zip)					
1. Name and Address of Reporting Person*  MPM Asset Management Investors BV2014 LLC							
(Last) C/O MPM CAPITA	(First)	(Middle)					
450 KENDALL STREET							
(Street) CAMBRIDGE	MA	02142					
(City)	(State)	(Zip)					
1. Name and Address of MPM BioVentu							
(Last)	(First)	(Middle)					
C/O MPM CAPITA 450 KENDALL ST							
(Street)  CAMBRIDGE	MA	02142					
(City)	(State)	(Zip)					
Name and Address o     MPM BioVentu	f Reporting Person* res 2014 GP LLC						
(Last) C/O MPM CAPITA 450 KENDALL ST		(Middle)					
(Street)							
CAMBRIDGE	MA	02142					
(City)	(State)	(Zip)					
1. Name and Address of Reporting Person*  MPM BIOVENTURES 2018, L.P.							
(Last) C/O MPM CAPITA 450 KENDALL ST		(Middle)					
	KELI						
(Street)  CAMBRIDGE	MA	02142					
(City)	(State)	(Zip)					
1. Name and Address of MPM BIOVEN	f Reporting Person* TURES 2018 (B), I	L.P.					
(Last) C/O MPM CAPITA	(First)	(Middle)					
450 KENDALL ST	REET						
(Street) CAMBRIDGE	MA	02142					
(City)	(State)	(Zip)					
1. Name and Address of MPM ASSET N		NVESTORS BV2018					
(Last) C/O MPM CAPITA	(First)	(Middle)					
450 KENDALL ST							
(Street) CAMBRIDGE	MA	02142					
(City)	(State)	(Zip)					
Explanation of Bospon							

## Explanation of Responses:

<sup>1.</sup> Each share of Series B Convertible Preferred stock is convertible at any time, at the Reporting Person's election, into Common Stock, based on the then-applicable conversion rate and has no expiration date. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein.

<sup>2.</sup> The shares of Series B Convertible Preferred stock held by MPM BioVentures 2014 LP ("BV 2014") will convert automatically into 1,269,230 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM BioVentures 2014 (B) LP ("BV 2014(B)") will convert automatically into 84,655 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Asset Management Investors BV 2014 LLC will convert automatically into 43,687 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM BioVentures 2018 LP ("BV 2018") will convert automatically into 801,619 shares of Common Stock upon the closing of the Issuer's initial public offering.

<sup>3. (</sup>Continued From footnote 2) The shares of Series B Convertible Preferred stock held by MPM BioVentures 2018 (B) LP ("BV 2018(B)") will convert automatically into 42,605 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Asset Management Investors BV 2018 LLC will convert automatically into 15,820 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by BV 2014 will convert automatically into 724,702 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by BV 2014(B) will convert automatically into 48,336 shares of Common Stock upon the closing of the Issuer's initial public offering.

- 4. (Continued From footnote 3) The shares of Series B-2 Convertible Preferred stock held by MPM Asset Management Investors BV 2014 LLC will convert automatically into 24,944 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by BV 2018 will convert automatically into 457,706 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by BV 2018(B) will convert automatically into 24,326 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Asset Management Investors BV 2018 LLC will convert automatically into 9,033 shares of Common Stock upon the closing of the Issuer's initial public offering. These amounts reflect a 1-for-3.3115 reverse stock split which became effective on July 20, 2020.
- 5. MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("2014 BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). Luke Evnin, Ansbert Gadicke and Todd Foley are the managing directors of 2014 BV LLC and members of MPM Asset Management Investors BV2014 LLC.
- 6. MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC ("2018 BV LLC") are the direct and indirect general partners of BV 2018 and BV 2018(B). Luke Evnin, Ansbert Gadicke, Todd Foley and Edward Hurwitz are the managing directors of 2018 BV LLC and members of MPM Asset Management Investors BV2018 LLC.
- 7. Each share of Series B-2 Convertible Preferred stock is convertible at any time, at the Reporting Person's election, into Common Stock, based on the then-applicable conversion rate and has no expiration date. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein.
- 8. On July 28, 2020, BV 2014 purchased 89,955 shares of Common Stock of the Issuer at a price of \$19.00 per share pursuant to an underwritten public offering.
- 9. On July 28, 2020, BV 2014(B) purchased 5,994 shares of Common Stock of the Issuer at a price of \$19.00 per share pursuant to an underwritten public offering.
- 10. On July 28, 2020, MPM Asset Management Investors BV 2014 LLC purchased 3,096 shares of Common Stock of the Issuer at a price of \$19.00 per share pursuant to an underwritten public offering.
- 11. On July 28, 2020, BV 2018 purchased 56,814 shares of Common Stock of the Issuer at a price of \$19.00 per share pursuant to an underwritten public offering.
- 12. On July 28, 2020, BV 2018(B) purchased 3,020 shares of Common Stock of the Issuer at a price of \$19.00 per share pursuant to an underwritten public offering.
- 13. On July 28, 2020, MPM Asset Management Investors BV 2018 LLC purchased 1,121 shares of Common Stock of the Issuer at a price of \$19.00 per share pursuant to an underwritten public offering,

## Remarks:

Form 1 of 2.

/s/ Ansbert Gadicke, managing director of MPM BioVentures 2014 LLC, the managing member of 07/29/2020 MPM BioVentures 2014 GP LLC, the general partner of MPM BioVentures 2014, L.P. /s/ Luke Evnin 07/29/2020 /s/ Todd Foley 07/29/2020 /s/ Ansbert Gadicke, managing director of MPM BioVentures 2014 LLC, the managing member of 07/29/2020 MPM BioVentures 2014 GP LLC. the general partner of MPM BioVentures 2014 (B), L.P. /s/ Howard Rubin, director of MPM Asset Management Investors 07/29/2020 **BV2014 LLC** /s/ Ansbert Gadicke, managing director of MPM BioVentures 2014 07/29/2020 /s/ Ansbert Gadicke, managing director of MPM BioVentures 2014
07/29/2020 LLC, the managing member of MPM BioVentures 2014 GP LLC /s/ Ansbert Gadicke, managing director of MPM BioVentures 2018 LLC, the managing member of 07/29/2020 MPM BioVentures 2018 GP LLC, the general partner of MPM BioVentures 2018, L.P. /s/ Ansbert Gadicke, managing director of MPM BioVentures 2018 LLC, the managing member of 07/29/2020 MPM BioVentures 2018 GP LLC, the general partner of MPM BioVentures 2018 (B), L.P. /s/ Howard Rubin, director of MPM 07/29/2020 Asset Management Investors **BV2018 LLC** \*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.